Wegovy was manufactured available in Europe’s most obese country on Sept. 4, in what Novo called a “managed and confined launch”. The Norwegian Medicines Agency claimed in January 2023 it wouldn't subsidise the drug, stating the price will be also substantial in relation on the documented health outcomes. This source https://shulamithw430kqv7.wikifiltraciones.com/user